Arrowhead Pharma Q1 EPS $(1.24) Misses $(0.82) Estimate, Sales $3.55M Miss $29.51M Estimate
Portfolio Pulse from mahesh@benzinga.com
Arrowhead Pharma (NASDAQ:ARWR) reported Q1 EPS of $(1.24), missing the $(0.82) estimate, and sales of $3.55M, missing the $29.51M estimate. This represents a significant decrease in performance compared to the same period last year.
February 06, 2024 | 9:07 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Arrowhead Pharma reported a significant miss in both EPS and sales for Q1, with a 217.95% decrease in EPS and a 94.32% decrease in sales compared to last year.
The substantial miss in both earnings per share and sales compared to analyst estimates, coupled with the significant decrease from the previous year's figures, is likely to negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100